Is TTK Healthcare overvalued or undervalued?

As of 20 June 2025, TTK Healthcare's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued. Key ratios include a PE ratio of 25.42, an EV to EBITDA of 29.72, and a PEG ratio of 2.03, which suggest that while the company is priced at a premium relative to its earnings growth potential, it remains competitive within its sector.
In comparison to its peers, TTK Healthcare's PE ratio is lower than that of Sun Pharma Industries at 34.92 and Divi's Laboratories at 79.84, both of which are classified as expensive. Meanwhile, Cipla and Dr. Reddy's Laboratories, both rated as attractive, have lower PE ratios of 22.99 and 19.56, respectively. Despite TTK Healthcare's recent stock performance lagging behind the Sensex over the past year, its strong historical returns over three and five years highlight its potential for recovery and growth in a favorable market environment.